country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-149263

Copy Link Print Information

HAA-09

HAA-09 is an orally active and potent anti-influenza agent, targeting the influenza PB2_cap binding domain. HAA-09 displays potent anti-influenza A virus activity, with an EC₅₀ of 0.03 μM. HAA-09 shows polymerase inhibition, with an IC₅₀ of 0.06±0.004 μM. HAA-09 blocks virus replication without causing obvious cytotoxicity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 1422051-33-9
Formel: C₁₇H₁₈F₂N₆O₂
Molecular Weight:376.36

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (273 KB)

HAA-09 Chemical Structure

CAS. Nr.: 1422051-33-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 0.06±0.004 μM (polymerase); EC50: 0.03 μM (influenza A virus)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A549	CC₅₀	>100 μM Compound: HAA-09	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 96 hrs by CCK-8 method Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 96 hrs by CCK-8 method	[PMID: 36773549]

In Vitro

HAA-09 exhibits a stronger antiviral activity against oseltamivir-sensitive A/WSN/33 and oseltamivir-resistant H275Y variant, superior to oseltamivir^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

HAA-09 exhibits high plasma stability (t_1/2≥12 h) and no obvious hERG inhibition^[1].
HAA-09 (0-25 mg/kg; Orally, BID) exhibits anti-influenza virus efficacy in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Balb/C mice^[1]
Dosage:

40 mg/kg
Administration:

Orally, QD (once daily) for consecutive 3 days
Result:

Demonstrated a favorable safety profile when orally administrated in healthy mice.

Animal Model:

Female BALB/c mice (6–8 weeks)^[1]
Dosage:

12.5, 25 mg/kg
Administration:

Orally, BID (twice daily) starting 48 h post infection for 9 days
Result:

Demonstrated in vivo therapeutic efficacy (85.7% survival observed at the day 15 post infection).

Chemical Information

CAS. Nr. 1422051-33-9
Molecular Weight 376.36
Formel C₁₇H₁₈F₂N₆O₂
SMILES

CC(C)(N(NC1=C(C=NC(C2=CNC3=C2C=C(C=N3)F)=N1)F)CC(O)=O)C
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Wang S, et al. Synthesis and structure-activity optimization of 7-azaindoles containing aza-β-amino acids targeting the influenza PB2 subunit. Eur J Med Chem. 2023 Mar 15;250:115185. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen